Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018140974 - PASSIVE ANTIBODY DEPENDENT CELL-MEDIATED ACTIVATION

Publication Number WO/2018/140974
Publication Date 02.08.2018
International Application No. PCT/US2018/016035
International Filing Date 30.01.2018
IPC
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/08 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
C07K 14/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 17/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
17Carrier-bound or immobilised peptides; Preparation thereof
C07K 2/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2Peptides of undefined number of amino acids; Derivatives thereof
C07K 4/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
4Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
CPC
A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 31/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
20for DNA viruses
22for herpes viruses
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • OHIO STATE INNOVATION FOUNDATION [US]/[US]
  • CALIGIURI, Michael [US]/[US]
  • YU, Jianhua [CN]/[US]
  • DAI, Hongsheng [CN]/[US]
Inventors
  • CALIGIURI, Michael
  • YU, Jianhua
  • DAI, Hongsheng
Agents
  • FENDRICK, Sarah, E.
Priority Data
62/452,11130.01.2017US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PASSIVE ANTIBODY DEPENDENT CELL-MEDIATED ACTIVATION
(FR) ACTIVATION À MÉDIATION CELLULAIRE DÉPENDANTE DES ANTICORPS PASSIFS
Abstract
(EN) Disclosed herein are methods, reagents, and pharmaceutical compositions for modulating immune effector cell activation that does not requirean antigen-specific antibody. The IgG Fc region is shown herein to contain both a domain that binds an FcγR on immune effector cells and a non-overlapping region or domain that can bind Fc binding proteins on target cells, and that it is capable of bridging immune effector cells and target cells expressing Fc binding proteins without use of the antigen-binding region (Fab) of the antibody. Therefore, also disclosed are methods of enhancing or inhibiting passive ADCC in subjects.
(FR) L'invention concerne des procédés, des réactifs et des compositions pharmaceutiques pour moduler l'activation des cellules effectrices immunitaires qui ne nécessitent pas un anticorps spécifique de l'antigène. La région Fc des IgG selon la présente invention contient à la fois un domaine qui se lie à une région Fcγ sur des cellules effectrices immunitaires et une région ou un domaine non chevauchant qui peut lier des protéines de liaison Fc sur des cellules cibles, et elle est capable d'un pontage de cellules effectrices immunitaires et des cellules cibles exprimant des protéines de liaison Fc sans utiliser la région de liaison à l'antigène (Fab) de l'anticorps. Par conséquent, l'invention concerne également des procédés d'amélioration ou d'inhibition de la cytotoxicité à médiation cellulaire dépendante des anticorps (ADCC) passive chez des sujets.
Latest bibliographic data on file with the International Bureau